Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

Moderna has experienced a significant decline in its stock price, dropping by 18.59% over the past week. This downturn ...

Moderna is counting on new mRNA products such as its experimental COVID-flu combo shot to offset slumping COVID vaccine sales ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...

US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million-pound battle against US rival Moderna over the Covid-19 vaccine.

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...

Discover the latest Wall Street trends: market declines, Q2 earnings highlights, and key stock moves from Tesla, Meta, Microsoft, and more.

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

The emerging technology promises better medicine, faster internet and more sustainable food production. It also comes with ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...